Summary
A follow-up study of 116 Type 1 (insulin-dependent) diabetic patients on long-term continuous subcutaneous insulin infusion was conducted after 4.5±0.2 years. The average HbA1c-value of these patients decreased by 1% to 6.7±0.1% during this observation period. Typical side effects of continuous subcutaneous insulin infusion such as skin inflammation at the catheter insertion site occurred with similar frequency as has been reported previously by other authors. Diabetic ketoacidosis (0.14 per patient year) and disabling hypoglycaemia (0.1 per patient year, including 0.05 hypoglycaemic coma per patient-year) occurred at substantially lower rates than in other comparable studies with Type 1 diabetic patients at a similar degree of metabolic control. Subgroup evaluation suggested that a normal (<5.6%) HbA1c-value at follow-up was associated with increased incidence of disabling hypoglycaemia, whereas poor metabolic control (HbA1c>7.5%) was associated with increased rates of skin complications and hospital treatment for ketoacidosis. Thus, under the policies of this diabetes centre, continuous subcutaneous insulin infusion has proved to be beneficial to a large proportion of experienced adult Type 1 diabetic patients, who voluntarily had opted for, and continued with, this particular mode of insulin treatment.
Article PDF
Similar content being viewed by others
References
Slama G, Hautecouverture M, Assan R, Tchobroutsky G (1974) One to five days of continuous intravenous insulin infusion in seven diabetic patients. Diabetes 23: 732–738
Pickup JC, Keen H, Parsons JA, Alberti KGMM (1978) Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1: 204–207
American Diabetes Association (1985) Policy statement: continuous subcutaneous insulin infusion. Diabetes 34: 946–947
Schade DS, Santiago JV, Skyler JS, Rizza RA (1983) Intensive insulin therapy. Excerpta Medica, Princeton NJ
Calabrese G, Bueti A, Santeusanio F, Giombolini A, Zega G, Angeletti G, Cartechini MG, Brunetti P (1982) Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study. Diabetes Care 5: 457–465
Home PD, Capaldo B, Burrin JM, Worth R, Alberti KGMM (1982) A cross-over comparison of continuous subcutaneous insulin infusion (CSII) against multiple injections in insulin-dependent diabetic subjects: improved control with CSII. Diabetes Care 4: 466–471
Nathan DM, Lou P, Avrouch J (1982) Intensive conventional and insulin pump therapy in adult type-I diabetes. Ann Intern Med 97: 31–36
Brink SJ, Stewart C (1986) Insulin pump treatment in insulin-dependent diabetes mellitus: children, adolescents, and young adults. JAMA 255: 617–621
Berger M, Sonnenberg GE, Chantelau E (1982) Insulin pump treatment for diabetes: some questions can be answered already. Clin Physiol 2: 351–355
Daubresse JC, Henrivaux P, Bailly A, Lemy C, Duchateau A (1983) Long-term management of insulin-treated diabetic patients with continuous subcutaneous insulin infusion. Diabete Metab (Paris) 9: 45–52
Chantelau E, Bockholt M, Lie KT, Broermann C, Sonnenberg GE, Berger M (1983) Diet and pump-treated diabetes: a long-term follow-up. Diabete Metab (Paris) 9: 277–282
The Kroc Collaborative Study Group (1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 311: 365–372
Bending JJ, Pickup JC, Keen H (1985) Frequency of diabetic ketoacidosis and hypoglycaemia coma during treatment with continuous subcutaneous insulin infusion. Audit of medial care. Am J Med 79: 685–691
Leichter SB, Schreiner ME, Reynolds LR, Bolick T (1985) Longterm follow-up of diabetic patients using insulin infusion pumps. Arch Intern Med 145: 1409–1412
Mecklenburg RS, Benson EA, Benson JW, Blumenstein BA, Fredlund PN, Guinn TS, Metz RJ, Nielsen RL (1985) Long-term metabolic control with insulin pump therapy. N Engl J Med 313: 465–468
Rønn B, Mathisen ER, Vang L, Lørup B, Deckert T (1987) Evaluation of insulin pump treatment under routine conditions. Diabetes Res Clin Pract 3: 191–196
Rønn B, Vang L, Deckert T (1988) Seven years of routine insulin pump treatment. In: 7th Workshop of the AIDSPIT-Study Group, booklet of abstracts. January 31–February 2, 1988, Igls (Austria)
Knight G, Jennings AM, Ward DJ (1988) Outcome of a 5-year programme of glycaemic control intensification using CSII. Diabetes 37 [Suppl 1] 25 A (Abstract)
WHO-Study Group (1985) Diabetes mellitus. Technical Report Series 727. Geneva (Switzerland)
Editorial (1978) The policy of the European Association for the Study of Diabetes on human investigation. Diabetologia 15: 431–432
Pickup JC, Rothwell D (1984) Technology and the diabetic patient. Med Biol Eng Comput 22: 385–400
Kraegen EW, Chisholm DJ (1984) Insulin response to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia 26: 208–213
Scheen A, Castillo M, Jandrain B, Krzentowski G, Henrivaux P, Luyckx AS, Lefebvre P (1984) Metabolic alterations after a two-hour nocturnal interruption of continuous subcutaneous insulin infusion. Diabetes Care 7: 338–342
Scheen AJ, Henrivaux P, Jandrain B, Lefebvre P (1986) Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion. Diabetes Care 9: 673–674 (Letter)
Chantelau E, Sonnenberg GE, Best F, Heding LG, Berger M (1984) Target fasting glycaemia for pump-treated type-I diabetics. Klin Wochenschr 62: 328–330
Sonnenberg GE, Chantelau E, Berger M (1873) Educational aspects of insulin pump treatment in type-I diabetic patients. In: Assal JP, Berger M, Canivet J, Gay N (eds) Handbook of diabetes education. Excerpta Medica, Amsterdam, pp 70–77
Chantelau E, Lange G, Sonnenberg GE, Berger M (1987) Acute cutaneous complications and catheter needle colonization during insulin pump treatment. Diabetes Care 10: 478–482
Assal JP, Mühlhauser I, Pernet A, Gfeller R, Jorgens V, Berger M (1985) Patient education as the basis for diabetes care in clinical practice and research. Diabetologia 28: 602–613
Mühlhauser I, Bruckner I, Berger M, Cheta D, Jörgens V, Ionescu-Tirgoviste C, Scholz V, Mincu I (1987) Evaluation of an intensified insulin treatment and teaching programme as routine management of Type-1 (insulin-dependent) diabetes: the Bucharest-Düsseldorf study. Diabetologia 30: 681–690
Champion MC, Behme M, Dupre J, Galbraith J, Radziuk J, Rodger NW, Ruston M (1981) Continuous subcutaneous infusion of insulin (CSII) in insulin-dependent diabetes mellitus: 17 subject years in 11 volunteers. Clin Invest Med 4: 33 B (Abstract)
Chantelau E, Gösseringer G, Sonnenberg GE, Berger M (1985) Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic outpatients. Diabetologia 28: 204–207
Chantelau E, Spraul M, Kunze K, Sonnenberg GE, Berger M (1986) Effects of the glycaemic index of dietary carbohydrates on prandial glycaemia and insulin therapy in type-I diabetes mellitus. Diabetes Res Clin Pract 2: 35–41
Melberg SG, Havelund S, Villumsen J, Brange J (1988) Insulin compatibility with polymer materials used in external pump infusion systems. Diabetic Med 5: 243–247
Marshall SM, Home PD (1986) Which pump? Diabetic Med 3: 190–191
The DCCT Research Group (1987) Diabetes control and complications trial (DCCT): results of a feasibility study. Diabetes Care 10: 1–19
National Diabetes Data Group (1984) Report of the expert comittee on glycosylated hemoglobin. Diabetes Care 7: 602–606
Little RR, England JD, Wiedmeyer H-M, McKenzie EM, Pettitt DJ, Knowler WC, Goldstein DE (1988) Relationship of glycosylated hemoglobin to oral glucose tolerance. Diabetes 37: 60–64
Mühlhauser I, Sawicki P, Berger M (1986) Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in Type 1 (insulin-dependent) diabetes. Diabetologia 29: 500–502
Morris JA, Gardner MJ (1988) Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J 196: 1313–1316
Pickup JC (1984) Pumps in practice: practical aspects of continuous subcutaneous insulin infusion (CSII). Diabetic Med 1: 27–32
Nathan DM, Singer DE, Hurxthal K, Goodson JD (1984) The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310: 341–346
Mann JI, Lewis B, Shepherd J, Winder AF, Fenster S, Rose L, Morgan B (1988) Blood lipid concentrations and other cardiovascular risk factors: distribution, prevalence, and detection in Britain. Br Med J 296: 1702–1706
Teusch SM, Herman WH, Dwyer D, Lane M (1984) Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med 310: 361–368
Schiffrin A, Belmonte M (1982) Multiple daily self-glucose monitoring: its essential role in long-term glucose control in insulin-dependent diabetic patients treated with pump and multiple subcutaneous injections. Diabetes Care 5: 479–484
Nathan DM (1983) The importance of intensive supervision in determining the efficacy of insulin pump therapy. Diabetes Care 6: 295–297
Peyrot M, Rubin RR (1988) Insulin self-regulation predicts better glycemic control. Diabetes 37 [Suppl 1]: 53 A (Abstract)
Mühlhauser I, Jansen M, Berger M (1988) How do c-peptide negative IDDM patients maintain normal glycosylated hemoglobin values? Diabetes 37 [Suppl 1]: 162 A (Abstract)
Peden NR, Braaten JT, McKendry JBR (1984) Diabetic ketoacidosis during long-term treatment with continuous subcutaneous insulin infusion. Diabetes. Care 7: 1–5
Knight G, Ward JD (1986) Diabetic ketoacidosis. Lancet II: 1284–1285 (Letter)
Pickup JC (1986) Indications, contraindications, and complications of continuous subcutaneous insulin infusion. In: Serrano-Rios M, Lefebvre PJ (eds) Diabetes 1985. Elsevier, Amsterdam, pp 900–903
Lauritzen T, Pramming S, Deckert T, Binder C (1983) Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 24: 326–329
Chisholm DJ, Kraegen EW, Hewett MJ, Purler S (1984) Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate. Diabetologia 27: 238–242
Skyler JS (1986) Lessons from studies of insulin pharmacokinetics. Diabetes Care 9: 666–668 (Editorial)
Home PD, Marshall SM (1984) Problems and safety of continuous subcutaneous insulin infusion. Diabetic Med 1: 41–44
Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL (1988) Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260: 2864–2871
Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D (1989) Glucose control and the renal and retinal complications of insulin dependent diabetes. JAMA 261: 1155–1160
Aaby Svendsen P, Lauritzen T, Søegaard U, Nerup J (1982) Glycosylated haemoglobin and steady-state mean blood-glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 23: 403–405
Bending JJ, Viberti GC, Bilous RW, Keen H (1985) Eight-month correction of hyperglycemia in insulin-dependent diabetes mellitus is associated with a significant and sustained reduction of urinary albumin excretion rate in patients with microalbuminuria. Diabetes 34 [Suppl 3]: 69–73
Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T (1985) Two year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34 [Suppl 3] 74–79
Tattersall RB, Gale E (1981) Patient self-monitoring of blood glucose and refinements of conventional insulin treatment. Am J Med 70: 177–181
Jarrett RJ, Keen H (1980) Towards a target blood glucose in diabetes. Lancet II: 30–31 (Letter)
Unger RH (1982) Meticulous control of diabetes: benefits, risks, and precautions. Diabetes 31: 479–483
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chantelau, E., Spraul, M., Mühlhauser, I. et al. Long-term safety, efficacy and side-effects of continuous subcutaneous insulin infusion treatment for Type 1 (insulin-dependent) diabetes mellitus: a one centre experience. Diabetologia 32, 421–426 (1989). https://doi.org/10.1007/BF00271261
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00271261